complement-5 SiRNA therapy (Eisai/Tokyo Women's Medical College/KAN Research Institute)

N/A

Report date: 2025/01/26 19:11:35
NME

Base Information

Drug Namecomplement-5 SiRNA therapy (Eisai/Tokyo Women's Medical College/KAN Research Institute)
Drug Alias NameC5 SiRNA therapy (Eisai/Tokyo Women's Medical College/KAN Research Institute)
ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsRejection of renal transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKobe Research Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesTokyo Women's Medical CollegeKobe Research LaboratoriesEisai Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A